Percutaneous Mitral Valve Therapy: The Next Decade
This article was originally published in Start Up
After more than a decade, the field of transcatheter mitral valve therapy is still in its infancy, yet it is surprisingly crowded. The first percutaneous mitral valve company was founded in 1999, the same year that the first transcatheter aortic valve implantation (TAVI) company was founded, but while TAVI is now on the market in Europe and in the US, the leading transcatheter mitral valve therapy has only just completed clinical trials. The anatomy of the mitral valve is much more complex than its aortic counterpart, patients with mitral valve disease make up a heterogeneous group, and the anatomical environment for mitral valve implants is much more challenging. Nevertheless, the potential market for transcatheter mitral valve treatments is at least four times that of TAVI, is wide open, and offers a substantial growth opportunity for strategic companies working in the cardiovascular space.
You may also be interested in...
You know times are tough for medtech start-ups in the US when even a successful serial entrepreneur like Michael Lesh, MD, is told by VCs, “We love your idea, but….” Middle Peak Medical, Lesh’s new start-up in the mitral valve space, solved its problem with a Series A financing round involving European investors and by co-locating itself in Germany and the US.
Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.
Now that transcatheter heart valves have been implanted in thousands of humans, it’s becoming clear where the problems lie. Vascular and bleeding complications, stroke and paravalvular leaks are the most troubling consequences. Most of the focus has been on improving the valves and the delivery systems, but now innovators are looking at the issue of access – the particular ways by which therapeutic devices enter the heart – and how it can be changed to improve outcomes. In this issue we profile Apica Cardiovascular, Entourage Medical and Inseal Medical.